Moderna goes after Alnylam, filing counterclaims in Spikevax patent suit
Moderna has gone on the offensive in its patent feud against Alnylam, filing two counterclaims against the RNAi drug developer after Alnylam’s patent suit.
The two 44-page documents, filed last Wednesday in Delaware district court, accuses Alnylam of “baselessly” looking to profit off Moderna’s multi-billion-dollar blockbuster Covid-19 vaccine and asked the court to declare Alnylam’s patent invalid. Moderna also said Alnylam has no claim against Moderna “to the extent Moderna used or manufactured Spikevax for the Government and ‘with the authorization or consent of the Government’ under 28 U.S.C. § 1498.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.